This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Cristina Caffara writes on the substantive implications of the ECJ’s Intel judgment for future cases from an economic perspective, and on the significance and role of the “as-efficient-competitor test” going forward.
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...
FTCWatch recently conducted an in-depth interview with Vice President Nate Goldstein, exploring his transition from a distinguished 23-year tenure at the...
CRA is a proud sponsor of the conference. Laurent Flochel moderates the opening discussion on “Mergers in the EU & US: What has changed?” For more information...
CRA is a proud sponsor of this event featuring a full-day program of insightful presentations and discussions on intellectual property valuation, damages...
